Fredun Pharmaceuticals Ltd

BSE: 539730
Fredun Pharmaceuticals Ltd - pharma in Mumbai, Maharashtra, India. FY 2026 financials and compliance.
CIN L24239MH1987PLC043662 Incorporated 08 June 1987 ROC Mumbai HQ Mumbai, Maharashtra, India
Active Listed - BSE: 539730 Public Limited Company pharma
Data last updated
Revenue · FY 2026
₹633.33 Cr
▲ 40.21% YoY
Computed EBITDA · FY 2026
₹94.54 Cr
▲ 72.17% YoY
Net profit · FY 2026
₹32.62 Cr
▲ 65.26% YoY
Authorised capital
₹50 Cr
Registered with MCA
Paid-up capital
₹5.51 Cr
Issued & subscribed
Open charges
₹293.76 Cr
Satisfied ₹172.61 Cr
Company age
39 yrs
Est. 1987
Employees · EPFO
388
Latest available

About Fredun Pharmaceuticals Ltd

Data last updated: 14 July 2026

Fredun Pharmaceuticals Ltd is a public limited company based in Mumbai, Maharashtra, India. It specialises in drug formulation and development, a part of the broader pharmaceuticals sector. Incorporated on 08 June 1987, the company has been in operation for over 39 years.

Registered with ROC Mumbai under CIN L24239MH1987PLC043662. Listed on BSE: 539730.

Capital: an authorised share capital of ₹50 Cr and a paid-up capital of ₹5.51 Cr. Formerly known as Fredun Pharmaceuticals Private Limited. It is led by directors including Daulat Nariman Medhora and Fredun Nariman Medhora.

Last AGM: 30 September 2025. Financial statements filed for year ended 31 March 2025. Office: Mumbai, Maharashtra.

As per BSE-filed consolidated financials for FY 2026, the company reported a revenue of ₹633.33 Cr, a growth of 40.21% compared to the previous year. The net worth stands at ₹278.11 Cr (up 96.71% YoY). Total assets are valued at ₹642.08 Cr (up 31.73% YoY).

The company has a workforce of approximately 388 employees as per the latest available data.

The company is associated with 1 brand - Fredun Group. As per MCA filings, the company has open charges of ₹293.76 Cr and satisfied charges of ₹172.61 Cr on record.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website fredungroup.com.

Company Details of Fredun Pharmaceuticals Ltd
CIN L24239MH1987PLC043662
Registration Number 043662
Incorporation Date 08 June 1987
ROC Mumbai
Listing Status Listed (BSE: 539730)
Company Status Active
Date of Last AGM 30 September 2025
Date of Balance Sheet 31 March 2025
Compliance Status Active Compliant
Key People
Fredun Nariman Medhora Managing Director Daulat Nariman Medhora Whole-Time Director Pooja Narendra Sanghavi Additional Director
Contact Details
  • Email
    Locked
  • Telephone
    Locked
  • Website
    fredungroup.com
  • Social Media
    Locked
  • Registered Address
    11Th Floor Tower A Urmi Estate, 95 Ganpatrao Kadam Marg Lower Parel (W), Mumbai, Maharashtra, India – 400013
  • Industry
    Pharma, Drug Formulation & Development
Company report
Fredun Pharmaceuticals Ltd - full intelligence report
  • Historical Financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Litigation, compliance and MCA filings
  • PDF report delivered after checkout
₹799 ₹999 20% off
Secure checkout · GST invoice included

Unlock the full Fredun Pharmaceuticals Ltd report

Financials, compliance, directors, charges, ownership and filings for Fredun Pharmaceuticals Ltd in one report.

10-year financials Directors & ownership Charges & compliance

CIN History of Fredun Pharmaceuticals Ltd

Fredun Pharmaceuticals Ltd has one previous CIN (Corporate Identification Number): U24239MH1987PLC043662. The current CIN is L24239MH1987PLC043662, which is the unique identifier assigned by the Registrar of Companies.

CIN Status
L24239MH1987PLC043662 Current
U24239MH1987PLC043662 Previous

Associated Brands with Fredun Pharmaceuticals Ltd

Fredun Pharmaceuticals Ltd operates one associated brand: Fredun Group. These brands represent Fredun Pharmaceuticals Ltd's diversified market presence and brand portfolio.

Brand Description Website
Fredun Group
Manufacturer of pharmaceutical formulations, APIs, and nutraceuticals fredungroup.com

Business Activity of Fredun Pharmaceuticals Ltd

Fredun Pharmaceuticals Ltd is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.

Main Activity Group Code Description of Main Activity Business Activity Code Description of Business Activity Turnover Percentage
C Manufacturing C6 Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products Locked
Premium access

Business activity turnover details for Fredun Pharmaceuticals Ltd

Turnover contribution percentages and historical activity changes require an active report plan.

  • Turnover contribution
  • Historical classifications
  • Filing-level activity changes

Verified entity values are shown only after access is granted.

Auditor Details of Fredun Pharmaceuticals Ltd

Fredun Pharmaceuticals Ltd is audited by R.H.Nisar & Co. (ICAI peer reviewed, certificate valid till 2026-09-30) for the financial year 2026, as reported in its BSE exchange filings. The statutory auditor is responsible for expressing an independent opinion on whether the financial statements present a true and fair view in accordance with applicable accounting standards.

Name Financial year Audit opinion
R.H.Nisar & Co. (ICAI peer reviewed, certificate valid till 2026-09-30) FY 2026 Declaration of unmodified opinion

Board of Directors of Fredun Pharmaceuticals Ltd

Fredun Pharmaceuticals Ltd is currently managed by 6 directors, with 12 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.

Current Directors
Name Designation Appointment Date Tenure Status
Daulat Nariman Medhora
Also directs: Fredun Pharmaceuticals Ltd, Fredun Healthcare Private Limited, Fredun Retail Private Limited and 3 more
Whole-Time Director 08 Jun 1987 39 Years 2 Months Current
Fredun Nariman Medhora
Also directs: Fredun Pharmaceuticals Ltd, Fredun Healthcare Private Limited, Fredun Retail Private Limited and 5 more
Managing Director 15 Sep 2006 19 Years 11 Months Current
Pooja Narendra Sanghavi
Also directs: Fredun Pharmaceuticals Ltd
Additional Director 28 Nov 2025 0 Years 8 Months Current
Anshu Gyan Agarwal
Also directs: Fredun Pharmaceuticals Ltd
Director 30 Jul 2025 1 Years 0 Months Current
Sonal Dharmin Desai
Also directs: Fredun Pharmaceuticals Ltd
Director 30 Jul 2025 1 Years 0 Months Current
Daisy Cyril Dsouza
Also directs: Fredun Pharmaceuticals Ltd, Sanjana Cryogenic Storages Limited
Director 24 Nov 2023 2 Years 8 Months Current
View all directors

Financials of Fredun Pharmaceuticals Ltd FY 2026 filings available

Fredun Pharmaceuticals Ltd reported revenue of ₹633.33 Cr (up 40.21% YoY) for FY 2026.

Revenue · FY 2026
₹633.33 Cr ▲ 40.21%
Profit · FY 2026
₹32.62 Cr ▲ 65.26%
Computed EBITDA · FY 2026
₹94.54 Cr ▲ 72.17%
Revenue₹ Cr · Consolidated0250500750FY 2025: ₹452 Cr452FY 2025FY 2026: ₹633 Cr · +40.2% YoY633+40.2%FY 2026
Net Profit₹ Cr · Consolidated02040FY 2025: ₹20 Cr19.7FY 2025FY 2026: ₹33 Cr · +65.3% YoY32.6+65.3%FY 2026
Quarterly Revenue₹ Cr · vs same quarter last year0100200300Q4'25: ₹165 Cr165Q4'25Q1'26: ₹119 Cr119Q1'26Q2'26: ₹144 Cr144Q2'26Q3'26: ₹160 Cr160Q3'26Q4'26: ₹210 Cr · +27.2% YoY210+27.2%Q4'26
Metrics FY 2026 FY 2025
Revenue from Operations ₹633.33 Cr ₹451.71 Cr
Other Income ₹5.8 Cr ₹4.56 Cr
Total Income ₹639.12 Cr ₹456.27 Cr
Cost of Materials Consumed ₹480.76 Cr ₹323.98 Cr
Purchases of Stock-in-Trade ₹0 ₹0
Changes in Inventories -₹31.69 Cr ₹6.05 Cr
Employee Benefit Expense ₹32.94 Cr ₹22.23 Cr
Finance Costs ₹39.3 Cr ₹22.38 Cr
Depreciation & Amortisation ₹8.25 Cr ₹5.04 Cr
Other Expenses ₹62.57 Cr ₹49.1 Cr
Total Expenses ₹592.13 Cr ₹428.78 Cr
Profit Before Exceptional Items & Tax ₹47 Cr ₹27.49 Cr
Exceptional Items ₹0 ₹0
Profit Before Tax ₹47 Cr ₹27.49 Cr
Total Tax Expense ₹14.38 Cr ₹7.75 Cr
Net Profit ₹32.62 Cr ₹19.74 Cr
  attributable to Owners - ₹0
  attributable to NCI - ₹19,000
Other Comprehensive Income ₹16.95 Lakh -₹34.35 Lakh
Total Comprehensive Income ₹32.79 Cr ₹19.4 Cr
EBITDA (computed) ₹94.54 Cr ₹54.91 Cr
Basic EPS ₹66.81 ₹44.83
Diluted EPS ₹61.23 ₹44.83
Metrics FY 2026 FY 2025
Total Assets ₹642.08 Cr ₹487.41 Cr
Non-current Assets ₹143.91 Cr ₹59.46 Cr
Current Assets ₹498.17 Cr ₹427.95 Cr
Property, Plant & Equipment ₹117.63 Cr ₹52.49 Cr
Inventories ₹269.8 Cr ₹239.89 Cr
Trade Receivables ₹92.69 Cr ₹177.12 Cr
Cash & Equivalents ₹64.93 Cr ₹63.69 Lakh
Equity (Net Worth) ₹278.11 Cr ₹141.38 Cr
Equity Share Capital ₹5.47 Cr ₹4.72 Cr
Borrowings (Non-current) ₹56.31 Cr ₹16.53 Cr
Borrowings (Current) ₹166.09 Cr ₹150.61 Cr
Total Debt (computed) ₹222.4 Cr ₹167.15 Cr
Current Liabilities ₹296.86 Cr ₹321.18 Cr
Total Liabilities ₹363.97 Cr ₹346.03 Cr
Metrics FY 2026 FY 2025
Operating Cash Flow ₹26.28 Cr -₹29.06 Cr
Investing Cash Flow -₹73.59 Cr -₹6.35 Cr
Financing Cash Flow ₹121.45 Cr ₹39.12 Cr
Capital Expenditure ₹73.59 Cr ₹6.11 Cr
Free Cash Flow (computed) -₹47.31 Cr -₹35.17 Cr
Dividends Paid ₹0 ₹0
Net Change in Cash ₹74.13 Cr ₹3.7 Cr
Metrics Q4 FY26 Q3 FY26 Q2 FY26 Q1 FY26 Q4 FY25
Revenue from Operations ₹210.41 Cr ₹159.93 Cr ₹143.59 Cr ₹119.4 Cr ₹165.44 Cr
Other Income ₹2.64 Cr ₹99.7 Lakh ₹1.71 Cr ₹45.21 Lakh ₹1.97 Cr
Total Income ₹213.06 Cr ₹160.92 Cr ₹145.29 Cr ₹119.86 Cr ₹167.41 Cr
Cost of Materials Consumed ₹173.54 Cr ₹118.91 Cr ₹100.44 Cr ₹91.08 Cr ₹125.01 Cr
Purchases of Stock-in-Trade ₹0 ₹0 ₹0 ₹0 ₹0
Changes in Inventories -₹22.09 Cr -₹7.35 Cr ₹4.41 Cr -₹6.66 Cr -₹1.23 Cr
Employee Benefit Expense ₹8.86 Cr ₹8.15 Cr ₹8.3 Cr ₹7.63 Cr ₹9.7 Cr
Finance Costs ₹14.49 Cr ₹10.55 Cr ₹7.73 Cr ₹6.53 Cr ₹8.15 Cr
Depreciation & Amortisation ₹3.15 Cr ₹1.78 Cr ₹1.89 Cr ₹1.42 Cr ₹1.84 Cr
Other Expenses ₹23.86 Cr ₹14.88 Cr ₹9.81 Cr ₹10.81 Cr ₹16.68 Cr
Total Expenses ₹201.81 Cr ₹146.92 Cr ₹132.59 Cr ₹110.81 Cr ₹160.14 Cr
Profit Before Exceptional Items & Tax ₹11.25 Cr ₹14 Cr ₹12.71 Cr ₹9.04 Cr ₹7.26 Cr
Exceptional Items ₹0 ₹0 ₹0 ₹0 ₹0
Profit Before Tax ₹11.25 Cr ₹14 Cr ₹12.71 Cr ₹9.04 Cr ₹7.26 Cr
Total Tax Expense ₹46.81 Lakh ₹3.52 Cr ₹3.27 Cr ₹2.27 Cr ₹1.26 Cr
Net Profit ₹10.78 Cr ₹10.48 Cr ₹9.43 Cr ₹6.77 Cr ₹6 Cr
  attributable to Owners - ₹0 ₹0 ₹0 ₹0
  attributable to NCI - ₹0 ₹0 ₹0 ₹0
Other Comprehensive Income ₹16.55 Lakh ₹0 ₹0 ₹0 -₹34.35 Lakh
Total Comprehensive Income ₹10.95 Cr ₹10.48 Cr ₹9.43 Cr ₹6.77 Cr ₹5.66 Cr
EBITDA (computed) ₹28.88 Cr ₹26.34 Cr ₹22.33 Cr ₹16.99 Cr ₹17.25 Cr
Basic EPS ₹19.70 ₹19.53 ₹19.98 ₹14.33 ₹12.71
Diluted EPS ₹18.22 ₹17.71 ₹19.98 ₹14.33 ₹12.71
Latest 5 quarters shown.
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Revenue from Operations ₹633.33 Cr ₹451.71 Cr ₹346.58 Cr ₹274.34 Cr ₹221.74 Cr ₹131.55 Cr ₹110.3 Cr ₹95.41 Cr
Other Income ₹5.8 Cr ₹4.56 Cr ₹2.49 Cr ₹2.16 Cr ₹4.35 Cr ₹3.74 Cr ₹2.99 Cr ₹2 Cr
Total Income ₹639.12 Cr ₹456.27 Cr ₹349.07 Cr ₹276.5 Cr ₹226.09 Cr ₹135.29 Cr ₹113.29 Cr ₹97.4 Cr
Cost of Materials Consumed ₹480.76 Cr ₹323.98 Cr ₹282.42 Cr ₹245.57 Cr ₹176.45 Cr ₹100.6 Cr ₹85.18 Cr ₹65.96 Cr
Purchases of Stock-in-Trade ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Changes in Inventories -₹31.69 Cr ₹6.05 Cr -₹22.44 Cr -₹37.72 Cr -₹58,000 ₹1.17 Cr -₹5.04 Cr -₹6.08 Cr
Employee Benefit Expense ₹32.94 Cr ₹22.23 Cr ₹12.5 Cr ₹11.53 Cr ₹10.66 Cr ₹8.66 Cr ₹8.95 Cr ₹8.04 Cr
Finance Costs ₹39.3 Cr ₹22.38 Cr ₹13.65 Cr ₹9.28 Cr ₹4.67 Cr ₹4.16 Cr ₹4.41 Cr ₹3.1 Cr
Depreciation & Amortisation ₹7.91 Cr ₹4.45 Cr ₹3.8 Cr ₹2.81 Cr ₹2.16 Cr ₹2 Cr ₹1.88 Cr ₹1.33 Cr
Other Expenses ₹62.32 Cr ₹48.91 Cr ₹37.69 Cr ₹27.52 Cr ₹23.56 Cr ₹14.33 Cr ₹9.45 Cr ₹18.9 Cr
Total Expenses ₹591.54 Cr ₹428 Cr ₹327.62 Cr ₹258.99 Cr ₹217.49 Cr ₹130.92 Cr ₹104.83 Cr ₹91.24 Cr
Profit Before Exceptional Items & Tax ₹47.58 Cr ₹28.27 Cr ₹21.45 Cr ₹17.51 Cr ₹8.6 Cr ₹4.37 Cr ₹8.46 Cr ₹6.16 Cr
Exceptional Items ₹0 ₹0 ₹0 ₹0 ₹0 -₹1.16 Cr ₹0 ₹0
Profit Before Tax ₹47.58 Cr ₹28.27 Cr ₹21.45 Cr ₹17.51 Cr ₹8.6 Cr ₹3.21 Cr ₹8.46 Cr ₹6.16 Cr
Total Tax Expense ₹14.38 Cr ₹7.46 Cr ₹5.83 Cr ₹6.7 Cr ₹2.26 Cr ₹1.19 Cr ₹59.27 Lakh ₹1.7 Cr
Net Profit ₹33.21 Cr ₹20.81 Cr ₹15.62 Cr ₹10.81 Cr ₹6.34 Cr ₹2.01 Cr ₹7.86 Cr ₹4.46 Cr
Other Comprehensive Income ₹16.55 Lakh -₹34.35 Lakh ₹7.04 Lakh -₹4.92 Lakh -₹2.25 Lakh -₹23,000 ₹0 ₹0
Total Comprehensive Income ₹33.37 Cr ₹20.46 Cr ₹15.69 Cr ₹10.76 Cr ₹6.31 Cr ₹2.01 Cr ₹7.86 Cr ₹4.46 Cr
EBITDA (computed) ₹94.79 Cr ₹55.1 Cr ₹38.9 Cr ₹29.6 Cr ₹15.43 Cr ₹10.54 Cr ₹14.75 Cr ₹10.59 Cr
Basic EPS ₹68.01 ₹44.83 ₹33.66 ₹22.93 ₹14.29 ₹5.05 ₹4.77 ₹11.17
Diluted EPS ₹62.33 ₹44.83 ₹33.32 ₹22.93 ₹14.29 ₹5.05 ₹4.77 ₹11.17
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Total Assets ₹642.14 Cr ₹486.65 Cr ₹307.6 Cr ₹257.28 Cr ₹186.99 Cr ₹161.62 Cr ₹133.16 Cr ₹104.91 Lakh Cr
Non-current Assets ₹143.89 Cr ₹59.12 Cr ₹50.4 Cr ₹41.07 Cr ₹34.34 Cr ₹31.54 Cr ₹32.05 Cr ₹32.39 Lakh Cr
Current Assets ₹498.24 Cr ₹427.53 Cr ₹257.2 Cr ₹216.21 Cr ₹152.65 Cr ₹130.08 Cr ₹101.11 Cr ₹72.52 Lakh Cr
Property, Plant & Equipment ₹117.61 Cr ₹52.14 Cr ₹46.15 Cr ₹38.63 Cr ₹32.28 Cr ₹30.32 Cr ₹30.93 Cr ₹31.35 Lakh Cr
Inventories ₹269.8 Cr ₹239.89 Cr ₹175 Cr ₹150.12 Cr ₹46.46 Cr ₹67.57 Cr ₹50.46 Cr ₹40.78 Lakh Cr
Trade Receivables ₹92.69 Cr ₹177.12 Cr ₹64.85 Cr ₹34.56 Cr ₹90.27 Cr ₹41.08 Cr ₹32.79 Cr ₹17.78 Lakh Cr
Cash & Equivalents ₹64.9 Cr ₹22.96 Lakh ₹1.07 Cr ₹2.95 Cr ₹1.94 Cr ₹99.46 Lakh ₹2.75 Cr ₹80,927 Cr
Equity (Net Worth) ₹278.71 Cr ₹141.4 Cr ₹121.47 Cr ₹96.38 Cr ₹68.06 Cr ₹43.07 Cr ₹41.32 Cr ₹38.99 Lakh Cr
Equity Share Capital ₹5.47 Cr ₹4.72 Cr ₹4.7 Cr ₹4.53 Cr ₹4.43 Cr ₹3.99 Cr ₹3.99 Cr ₹398,963 Cr
Borrowings (Non-current) ₹56.31 Cr ₹9.61 Cr ₹5.15 Cr ₹48.93 Cr ₹42.04 Cr ₹29.11 Cr ₹11.5 Cr ₹0
Borrowings (Current) ₹165.72 Cr ₹156.79 Cr ₹100.36 Cr ₹37.6 Cr ₹10.73 Cr ₹10.53 Cr ₹23.41 Cr ₹0
Total Debt (computed) ₹222.03 Cr ₹166.41 Cr ₹105.51 Cr ₹86.52 Cr ₹52.76 Cr ₹39.64 Cr ₹34.9 Cr ₹0
Current Liabilities ₹296.31 Cr ₹327.32 Cr ₹174.47 Cr ₹106.17 Cr ₹73.75 Cr ₹86.46 Cr ₹77.78 Cr ₹38.18 Lakh Cr
Total Liabilities ₹363.43 Cr ₹345.25 Cr ₹186.13 Cr ₹160.9 Cr ₹118.93 Cr ₹118.55 Cr ₹91.84 Cr ₹65.92 Lakh Cr
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022
Operating Cash Flow ₹30.81 Cr -₹28.88 Cr -₹43.87 Lakh -₹14.41 Cr -₹2.38 Cr
Investing Cash Flow -₹73.58 Cr -₹5.99 Cr -₹7.64 Cr -₹9.4 Cr -₹4.14 Cr
Financing Cash Flow ₹121.82 Cr ₹38.34 Cr ₹5.99 Cr ₹25.18 Cr ₹7.47 Cr
Capital Expenditure ₹73.58 Cr ₹5.99 Cr ₹7.64 Cr ₹0 ₹0
Free Cash Flow (computed) -₹42.77 Cr -₹34.88 Cr -₹8.08 Cr -₹14.41 Cr -₹2.38 Cr
Dividends Paid ₹0 ₹0 ₹0 ₹0 ₹0
Net Change in Cash ₹79.05 Cr ₹3.47 Cr -₹2.08 Cr ₹1.36 Cr ₹94.36 Lakh
The cash-flow statement became part of the exchange results-filing format in FY2022 - earlier years were not filed and are hidden.
Metrics Q4 FY26 Q3 FY26 Q2 FY26 Q1 FY26 Q4 FY25 Q3 FY25 Q2 FY25 Q1 FY25
Revenue from Operations ₹210.41 Cr ₹159.93 Cr ₹143.59 Cr ₹119.4 Cr ₹165.44 Cr ₹101.84 Cr ₹106.89 Cr ₹77.54 Cr
Other Income ₹2.64 Cr ₹99.7 Lakh ₹1.71 Cr ₹45.21 Lakh ₹1.97 Cr ₹85.58 Lakh ₹46.16 Lakh ₹1.28 Cr
Total Income ₹213.05 Cr ₹160.92 Cr ₹145.29 Cr ₹119.86 Cr ₹167.41 Cr ₹102.7 Cr ₹107.35 Cr ₹78.81 Cr
Cost of Materials Consumed ₹173.54 Cr ₹118.91 Cr ₹99.26 Cr ₹91.08 Cr ₹125.01 Cr ₹72.66 Cr ₹67.4 Cr ₹57.88 Cr
Purchases of Stock-in-Trade ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Changes in Inventories -₹22.09 Cr -₹7.35 Cr ₹4.41 Cr -₹6.66 Cr -₹1.23 Cr -₹26.07 Lakh ₹7.87 Cr -₹32.68 Lakh
Employee Benefit Expense ₹8.86 Cr ₹8.15 Cr ₹8.3 Cr ₹7.63 Cr ₹9.7 Cr ₹5.85 Cr ₹3.58 Cr ₹3.1 Cr
Finance Costs ₹14.49 Cr ₹10.55 Cr ₹7.73 Cr ₹6.53 Cr ₹8.15 Cr ₹5 Cr ₹5.31 Cr ₹3.91 Cr
Depreciation & Amortisation ₹3.11 Cr ₹1.78 Cr ₹1.6 Cr ₹1.42 Cr ₹1.25 Cr ₹1.09 Cr ₹1.06 Cr ₹1.05 Cr
Other Expenses ₹23.61 Cr ₹14.88 Cr ₹10.99 Cr ₹10.81 Cr ₹16.49 Cr ₹11.22 Cr ₹14.55 Cr ₹7.68 Cr
Total Expenses ₹201.52 Cr ₹146.92 Cr ₹132.29 Cr ₹110.81 Cr ₹159.37 Cr ₹95.56 Cr ₹99.78 Cr ₹73.29 Cr
Profit Before Exceptional Items & Tax ₹11.53 Cr ₹14 Cr ₹13.01 Cr ₹9.04 Cr ₹8.04 Cr ₹7.13 Cr ₹7.58 Cr ₹5.52 Cr
Exceptional Items ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Profit Before Tax ₹11.53 Cr ₹14 Cr ₹13.01 Cr ₹9.04 Cr ₹8.04 Cr ₹7.13 Cr ₹7.58 Cr ₹5.52 Cr
Total Tax Expense ₹46.81 Lakh ₹3.52 Cr ₹3.27 Cr ₹2.27 Cr ₹96.99 Lakh ₹1.8 Cr ₹3.3 Cr ₹1.39 Cr
Net Profit ₹11.07 Cr ₹10.48 Cr ₹9.73 Cr ₹6.77 Cr ₹7.07 Cr ₹5.33 Cr ₹4.27 Cr ₹4.13 Cr
Other Comprehensive Income ₹16.55 Lakh ₹0 ₹0 ₹0 -₹34.35 Lakh ₹0 ₹0 ₹0
Total Comprehensive Income ₹11.23 Cr ₹10.48 Cr ₹9.73 Cr ₹6.77 Cr ₹6.73 Cr ₹5.33 Cr ₹4.27 Cr ₹4.13 Cr
EBITDA (computed) ₹29.13 Cr ₹26.34 Cr ₹22.34 Cr ₹16.99 Cr ₹17.44 Cr ₹13.23 Cr ₹13.95 Cr ₹10.48 Cr
Basic EPS ₹20.22 ₹19.53 ₹20.61 ₹14.33 ₹14.98 ₹11.29 ₹9.05 ₹8.79
Diluted EPS ₹18.70 ₹17.71 ₹20.61 ₹14.33 ₹14.98 ₹11.29 ₹9.05 ₹8.79
Latest 8 quarters shown.
Want more history and ratios?
You're viewing the latest exchange-filed financials for Fredun Pharmaceuticals Ltd. The full report adds 10+ years of line-item history, 20+ ratios, peer benchmarks and a downloadable PDF.
10+ years of history 20+ ratios & benchmarks Downloadable PDF

Shareholding Pattern of Fredun Pharmaceuticals Ltd

As per the shareholding pattern filed with BSE for the quarter ended Mar 2026, promoters hold 44.17%, foreign institutional investors hold 1.06%, domestic institutional investors hold 2.83%, retail and other public shareholders hold 51.94% of Fredun Pharmaceuticals Ltd. The company had 8,338 shareholders on record.

Promoters: 44.17%DII (Domestic Institutional): 2.83%FII (Foreign Institutional): 1.06%Retail & Others: 51.94%
Mar 2026
QUARTER
44.17% Promoters
2.83% DII (Domestic Institutional)
1.06% FII (Foreign Institutional)
51.94% Retail & Others
Promoter holding - history
Now 44.17% · Mar 2026High 49.62% · Jun 2023Low 43.06% · Dec 2025
42%44.3%46.5%48.8%51%Jun 2023Dec 2023Jun 2024Dec 2024Jun 2025Dec 2025Jun 2023: 49.62%Sep 2023: 49.31%Dec 2023: 49.16%Mar 2024: 49.17%Jun 2024: 49.17%Sep 2024: 48.93%Dec 2024: 48.93%Mar 2025: 48.93%Jun 2025: 48.93%Sep 2025: 48.93%Dec 2025: 43.06%Mar 2026: 44.17%49.62%43.06%44.17%
Shareholding trend - last 6 quarters
Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Promoters44.17%43.06%48.93%48.93%48.93%48.93%
Public55.83%56.94%51.07%51.07%51.07%51.07%
Shareholding history - year on year (as at 31 March)
Mar 2026Mar 2025Mar 2024
Promoters44.17%48.93%49.17%
Public55.83%51.07%50.83%
Promoter change (YoY, %pts)-4.76-0.24-

Charges & Borrowings of Fredun Pharmaceuticals Ltd

Open charges
₹293.76 Cr
Satisfied charges
₹172.61 Cr
Breakdown by lending institutions
Others₹166.79 Cr
Hdfc Bank Limited₹84.50 Cr
State Bank of India₹40.00 Cr
Yes Bank Limited₹1.28 Cr
Axis Bank Limited₹1.18 Cr
Latest charge details
DateLenderAmountStatus
07 May 2026 Others ₹2 Cr Open
30 Apr 2026 Others ₹1.06 Cr Open
15 Apr 2026 Others ₹35 Cr Open
26 Feb 2026 Others ₹20 Cr Open
22 Feb 2026 Others ₹3.78 Cr Open

Total charge records: 83 View all charges

Employees and EPFO Compliance at Fredun Pharmaceuticals Ltd

Fredun Pharmaceuticals Ltd has a workforce of 388 employees as of Jan 08, 2026.

Employee count
388
Active EPFO establishments
1
Employee growth
37.59%
Premium access

Employee and EPFO history for Fredun Pharmaceuticals Ltd

Monthly headcount, contribution history, establishment records, and filing compliance require an active report plan.

  • Monthly headcount
  • PF contributions
  • ECR filing status
  • Establishment history

Verified entity values are shown only after access is granted.

GST Compliance of Fredun Pharmaceuticals Ltd

Premium access

GST registrations and filing compliance for Fredun Pharmaceuticals Ltd

State-wise registrations, return filing status, HSN and SAC details, and jurisdiction records require an active report plan.

  • GSTIN registrations
  • State-wise filing status
  • HSN and SAC details
  • Tax jurisdiction records

Verified entity values are shown only after access is granted.

Credit Ratings, Litigation & Regulatory Alerts for Fredun Pharmaceuticals Ltd

Premium access

Credit ratings, litigation, and regulatory alerts for Fredun Pharmaceuticals Ltd

Agency ratings, court records, regulatory events, and entity-specific compliance alerts require an active report plan.

  • Rating history
  • Court and tribunal cases
  • Regulatory alerts
  • Director-linked violations

Verified entity values are shown only after access is granted.

MSME Payment Delays by Fredun Pharmaceuticals Ltd

Premium access

MSME payment history for Fredun Pharmaceuticals Ltd

Amounts outstanding to micro and small suppliers, delay reasons, and MSME-1 filing history require an active report plan.

  • Outstanding amounts
  • Delay periods and reasons
  • MSME-1 filing history
  • Vendor payment signals

Verified entity values are shown only after access is granted.

Subsidiaries & Group Companies of Fredun Pharmaceuticals Ltd

Premium access

Corporate group structure for Fredun Pharmaceuticals Ltd

Parent, subsidiary, associate, joint venture, and ownership records require an active report plan.

  • Parent company
  • Subsidiaries and ownership
  • Associates and joint ventures
  • Entity investments

Verified entity values are shown only after access is granted.

MCA Filings & Documents of Fredun Pharmaceuticals Ltd

Premium access

MCA filings and documents for Fredun Pharmaceuticals Ltd

Official forms, annual returns, financial statements, charge filings, and document dates require an active report plan.

  • Incorporation documents
  • Annual returns and statements
  • Charge filings
  • Complete filing index

Verified entity values are shown only after access is granted.

Recent Activity on Fredun Pharmaceuticals Ltd

Charges
07 May 2026
A charge with Others amounted to Rs. 2.00 Cr with Charge ID 101292093 was registered on 07 May 2026.
Charges
30 Apr 2026
A charge with Others amounted to Rs. 1.06 Cr with Charge ID 101295920 was registered on 30 Apr 2026.
Charges
15 Apr 2026
A charge with Others amounted to Rs. 35.00 Cr with Charge ID 101288117 was registered on 15 Apr 2026.
Charges
07 Apr 2026
A charge registered on 07 Apr 2021 via Charge ID 100440779 with Others was fully satisfied on 07 Apr 2026.
Charges
07 Apr 2026
A charge registered on 23 Dec 2020 via Charge ID 100404061 with Others was fully satisfied on 07 Apr 2026.
Charges
07 Apr 2026
A charge registered on 16 Jul 2019 via Charge ID 100278346 with Others was fully satisfied on 07 Apr 2026.

Frequently Asked Questions about Fredun Pharmaceuticals Ltd

Fredun Pharmaceuticals Ltd is an active public limited company in the pharma sector based in Mumbai, Maharashtra, India. It was incorporated on 08 June 1987 (39+ years old) and is registered under CIN L24239MH1987PLC043662. Listed on BSE: 539730. The company has 388 employees.

Fredun Pharmaceuticals Ltd reported revenue of ₹633.33 Cr for FY 2026 (up 40.21% YoY) based on consolidated BSE filings.

The current directors of Fredun Pharmaceuticals Ltd are:

The primary industry of Fredun Pharmaceuticals Ltd is pharma. The company specifically operates in drug formulation and development. The company is currently active in this sector.

Yes. Fredun Pharmaceuticals Ltd is listed on BSE with code 539730.

Fredun Pharmaceuticals Ltd can be reached at the registered office: 11Th Floor Tower A Urmi Estate, 95 Ganpatrao Kadam Marg Lower Parel W, Mumbai, Maharashtra, India – 400013, or through the website fredungroup.com.

7M+ Indian companies. One platform.

Financials, directors, compliance, charges and shareholding - sourced from MCA, SEBI and RBI filings.

Subscription plans available